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Abstract
Background: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR,
daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus
bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM).
Methods: This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using
fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16),
and/or del17p abnormalities. Minimal residual disease (MRD; 10−5 sensitivity threshold) was assessed via the
clonoSEQ® assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group
were categorized as high risk.
Results: After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard
(16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21–0.83;
P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained
MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall
population of CASTOR.
Conclusion: These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for
RRMM, regardless of cytogenetic risk status.
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Background
Daratumumab is a human IgGκ monoclonal antibody tar-
geting CD38 with a direct on-tumor [1–4] and immuno-
modulatory mechanism of action [5–7]. Intravenous
daratumumab 16mg/kg is approved as monotherapy in
patients with heavily pre-treated relapsed or refractory
multiple myeloma (RRMM) and in combination with bor-
tezomib/dexamethasone (Vd) or lenalidomide/dexametha-
sone (Rd) in patients with multiple myeloma (MM) who
received at least 1 prior line of therapy and in combination
with pomalidomide/dexamethasone in patients with at
least 2 prior therapies, including lenalidomide and a
proteasome inhibitor [8]. Daratumumab is also approved
in combination with bortezomib/melphalan/prednisone
and in combination with Rd in patients with transplant-
ineligible newly diagnosed MM, and in combination with
bortezomib/thalidomide/dexamethasone in patients with
transplant-eligible newly diagnosed MM [8].
In the primary analysis of the phase 3 CASTOR study of
daratumumab plus Vd (D-Vd) versus Vd alone in patients
with RRMM, at a median follow-up of 7.4 months, D-Vd
significantly prolonged progression-free survival (PFS) and
increased rates of minimal residual disease (MRD) nega-
tivity and demonstrated a tolerable safety profile [9, 10].
With more than 3 years of follow-up (median 40.0
months) and compared with patients receiving Vd only,
patients receiving D-Vd demonstrated a 69% reduction in
the risk of disease progression or death (median PFS, 16.7
months vs 7.1 months; hazard ratio [HR], 0.31; 95%
confidence interval [CI], 0.25–0.40; P < 0.0001); showed
significantly better overall response rates (85% vs 63%;
P < 0.0001); and achieved better rates of complete re-
sponse (CR) or better (30% vs 10%; P < 0.0001), very good
partial response (VGPR) or better (63% vs 29%;
P < 0.0001), and MRD negativity at the 10−5 sensitivity
threshold (14% vs 2%; P < 0.000001) [11]. Patients who re-
ceived 1 prior line of therapy demonstrated the greatest
benefit with D-Vd, including a 78% reduction in the risk
of disease progression or death versus Vd (median PFS,
27.0months vs 7.9 months; HR, 0.22; 95% CI, 0.15–0.32;
P < 0.0001) and a response of CR or better (43% vs 15%;
P < 0.0001) and MRD negativity (10−5; 20% vs 3%;
P = 0.000025). In CASTOR, no new safety concerns were
observed with longer follow-up [11].
Patients with MM and specific cytogenetic markers
are at higher risk for poor outcomes [12, 13]. The Inter-
national Myeloma Working Group recommends defin-
ing high cytogenetic risk as testing positive for at least 1
of the following abnormalities: t(4;14), t(14;16), or
del17p, determined by fluorescence in situ hybridization
(FISH) [14]. This subgroup analysis of CASTOR pre-
sents updated efficacy and safety findings for D-Vd ver-
sus Vd treatment based on cytogenetic risk status after a
median follow-up of 40.0 months.
Methods
Patients
Complete study methodology and primary results from
CASTOR have been previously described [9, 15]. Briefly,
eligible patients received at least 1 prior line of MM
therapy, with at least a partial response to at least 1 prior
MM therapy, and had documented progressive disease
during or after their last regimen, as defined by the
International Myeloma Working Group criteria [16, 17].
Key exclusion criteria included the following: creatinine
clearance ≤ 20 mL/min/1.73 m2 body surface area, dis-
ease refractory or intolerant to bortezomib, disease re-
fractory to a different proteasome inhibitor, or presence
of grade ≥ 2 peripheral neuropathy or neuropathic pain.
Study design and treatment
CASTOR is a multicenter, randomized, open-label, active-
controlled, phase 3 trial enrolling patients with RRMM.
Randomization was stratified by the International Staging
System (stage I, II, or III) at screening, the number of prior
lines of therapy (1 vs 2 or 3 vs > 3), and previous bortezo-
mib treatment (no vs yes). The study protocol was ap-
proved by an independent ethics committee or
institutional review board at each study center and was
conducted in accordance with the principles of the Dec-
laration of Helsinki and the International Conference on
Harmonisation Good Clinical Practice guidelines. All pa-
tients provided written informed consent.
Patients were randomly assigned 1:1 to receive D-Vd
or Vd. All patients received eight 21-day cycles of Vd.
Bortezomib (1.3 mg/m2) was administered subcutane-
ously on days 1, 4, 8, and 11 during cycles 1 through 8.
Dexamethasone (20 mg) was given orally or intraven-
ously on days 1, 2, 4, 5, 8, 9, 11, and 12 during cycles 1
through 8. Daratumumab (16 mg/kg) was administered
intravenously to patients in the D-Vd group once weekly
during cycles 1 through 3, once every 3 weeks during cy-
cles 4 through 8, and once every 4 weeks thereafter until
disease progression. Patients in the Vd group were to re-
ceive a maximum of 8 cycles of Vd followed by observa-
tion until disease progression; following the primary
analysis, patients whose disease progressed could choose
to receive daratumumab monotherapy.
Cytogenetic risk
Cytogenetic risk was evaluated using local FISH or
karyotyping. Determination of each abnormality and
threshold of frequencies to consider a positive finding
was determined locally and varied by site. Patients in the
intent-to-treat (ITT) population who had at least 1 FISH
or karyotyping assessment were included in the analysis.
High-risk patients were defined as having 1 or more of
the following cytogenetic abnormalities identified:
t(4;14), t(14;16), or del17p.
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Table 1 Patient demographics, baseline disease, and clinical characteristics
Standard cytogenetic riska High cytogenetic riska,b
Characteristic D-Vd (n = 141) Vd (n = 140) D-Vd (n = 40) Vd (n = 35)
Age, years
Median (range) 64 (40–88) 64 (33–85) 63 (37–79) 59 (37–81)
≥ 75 years, n (%) 9 (6) 20 (14) 4 (10) 5 (14)
Sex, n (%)
Male 79 (56) 89 (64) 22 (55) 18 (51)
Race, n (%)
White 123 (87) 123 (88) 33 (83) 31 (89)
Black or African American 9 (6) 2 (1) 1 (3) 1 (3)
Asian 8 (6) 8 (6) 4 (10) 2 (6)
Native Hawaiian or other Pacific Islander 1 (1) 0 0 0
Other 0 1 (1) 0 0
Unknown/not reported 0 6 (4) 2 (5) 1 (3)
ISS stage, n (%)c
I 48 (34) 55 (39) 22 (55) 14 (40)
II 57 (40) 56 (40) 11 (28) 16 (46)
III 36 (26) 29 (21) 7 (18) 5 (14)
ECOG performance status score, n (%)
0 54 (38) 64 (46) 16 (40) 15 (43)
1 78 (55) 62 (44) 22 (55) 19 (54)
2 9 (6) 14 (10) 2 (5) 1 (3)
Cytogenetic profile, n (%)a,b
t(4;14) – – 13 (33) 15 (43)
t(14;16) – – 4 (10) 5 (14)
del17p – – 27 (68) 20 (57)
≥ 2 risk factorsd – – 4 (10) 4 (11)
Median (range) time from diagnosis, years 4.3 (0.7–20.7) 3.6 (0.6–18.6) 3.3 (1.0–10.5) 3.7 (1.0–14.8)
Prior lines of therapy, n (%)
1 70 (50) 67 (48) 21 (53) 12 (34)
2 32 (23) 40 (29) 11 (28) 15 (43)
3 25 (18) 16 (11) 5 (13) 6 (17)
> 3 14 (10) 17 (12) 3 (8) 2 (6)
Median (range) 2 (1–9) 2 (1–10) 1 (1–6) 2 (1–4)
Prior ASCT, n (%) 90 (64) 79 (56) 27 (68) 21 (60)
Prior PI, n (%) 101 (72) 94 (67) 27 (68) 28 (80)
Bortezomib 98 (70) 89 (64) 25 (63) 26 (74)
Prior IMiD, n (%) 104 (74) 110 (79) 28 (70) 29 (83)
Lenalidomide 52 (37) 66 (47) 15 (38) 17 (49)
Prior PI + IMiD, n (%) 73 (52) 67 (48) 15 (38) 22 (63)
Refractory to PI only, n (%) 1 (1) 2 (1) 2 (5) 1 (3)
Refractory to IMiD only, n (%) 41 (29) 51 (36) 12 (30) 11 (31)
Refractory to PI and IMiD, n (%) 6 (4) 2 (1) 0 4 (11)
Refractory to last line of therapy, n (%) 40 (28) 48 (34) 11 (28) 14 (40)
D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone, ISS International Staging System, ECOG Eastern Cooperative Oncology Group,
ASCT autologous stem cell transplantation, PI proteasome inhibitor, IMiD immunomodulatory drug, FISH fluorescence in situ hybridization
Note: percentages may not equal 100% due to rounding
aBased on FISH/karyotype testing
bPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
cISS stage is derived based on the combination of serum β2-microglobulin and albumin
dPatients with ≥ 2 of the t(4;14), t(14;16), or del17p risk factors
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MRD evaluation
MRD was evaluated at the time of the suspected CR (in-
cluding stringent CR; blinded to treatment group) and at
6 and 12months after the first treatment dose (i.e., at
the end of Vd therapy and 6months later, respectively).
Additional MRD evaluations were required every 12
months after CR. MRD was evaluated by next-
generation sequencing using the clonoSEQ® assay V2.0
(Adaptive Biotechnologies, Seattle, WA, USA) at a sensi-
tivity threshold of 10−5 (1 cancer cell per 100,000 nucle-
ated cells). Patients were considered MRD positive if
they had an MRD-positive or indeterminate test result
or were not assessed. Sustained MRD negativity was de-
fined as maintenance of MRD negativity at the 10−5 sen-
sitivity threshold for at least 6 months or at least 12
months.
Statistical analyses and assessments
The primary endpoint of the study was PFS. Exploratory
analyses were performed for subgroups of patients based
on cytogenetic risk status. PFS was assessed in patients
in the ITT population who met the biomarker criteria
for risk assessment. The response-evaluable analysis set
included patients who had measurable disease at the
baseline or screening visit and who received at least 1
study treatment and had at least 1 post-baseline disease
assessment. The safety population comprised individuals
who received at least 1 administration of study
treatment.
PFS and time to response were compared between the
D-Vd and Vd groups using a stratified log-rank test. A
Cox proportional hazards model was used to estimate
HRs and 95% CIs, with treatment as the sole explanatory
variable. The Kaplan-Meier method was used to estimate
distributions. PFS on the subsequent line of therapy
(PFS2) was defined as the time from randomization to
progressive disease after the next line of subsequent
therapy or death. Differences between treatment groups
for overall response rates, VGPR or better rates, and CR
or better rates were measured by a stratified Cochran-
Mantel-Haenszel chi-square test.
Patients in the ITT population who met the biomarker
criteria for risk assessment were evaluated for MRD and
sustained MRD negativity to allow for stringent and un-
biased evaluation. MRD-negativity rates were defined as
the proportions of patients achieving MRD-negative sta-
tus at any time after the first treatment dose and were
compared between the D-Vd and Vd treatment groups
using a Fisher’s exact test.
Results
Patients and treatments
A total of 498 patients were randomized, with 251
assigned to D-Vd and 247 assigned to Vd. A total of 356
(71%) patients underwent cytogenetic testing; 283 (57%)
patients were evaluated using FISH, 217 (44%) patients
were evaluated using karyotyping, and 144 (29%) were
evaluated using both. Of these, 40 (16%) patients in the
D-Vd group and 35 (14%) patients in the Vd group had
high cytogenetic risk abnormalities. Forty of 158 patients
in the D-Vd group and 35 of 173 patients in the Vd
group who underwent FISH testing were defined as high
risk. Two of 130 patients in the D-Vd group and 1 of
136 patients in the Vd group who underwent karyotype
testing were defined as high risk. A total of 141 (56%)
patients in the D-Vd group and 140 (57%) patients in
the Vd group had standard cytogenetic risk. Patient
demographics, baseline disease, and clinical characteris-
tics stratified by cytogenetic risk status are shown in
Table 1. Among patients achieving CR or better, MRD
was not evaluated in 15 (16%) patients. Overall, 170
(62%) and 50 (68%) patients in the standard and high
cytogenetic risk subgroups discontinued the treatment,
respectively (Table 2). Among patients who received Vd
Table 2 Patient disposition based on cytogenetic risk status
Standard riska High riska,b
Treatment discontinuation, n (%)c D-Vd (n = 137) Vd (n = 136) D-Vd (n = 40) Vd (n = 34)
Patients who discontinued treatment 108 (79) 62 (46) 33 (83) 17 (50)
Reason for discontinuation
Progressive disease 86 (63) 34 (25) 27 (68) 12 (35)
Adverse event 11 (8) 15 (11) 5 (13) 3 (9)
Noncompliance with study drugd 5 (4) 5 (4) 0 1 (3)
Withdrawal by patient 1 (1) 6 (4) 0 1 (3)
Death 2 (1) 2 (1) 1 (3) 0
Physician decision 3 (2) 0 0 0
D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone, FISH fluorescence in situ hybridization
aBased on FISH/karyotyping
bPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
cSafety population
dBased on reason “Patient refused to further study treatment” at “End of treatment”
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and discontinued treatment due to progressive disease, 9
of 34 and 2 of 12 patients in the standard and high cyto-
genetic risk subgroups, respectively, received daratumu-
mab monotherapy as subsequent therapy.
Updated efficacy results
After a median follow-up of 40.0months, treatment with
D-Vd prolonged median PFS compared with Vd alone in
patients with standard cytogenetic risk (16.6months vs 6.6
months; HR, 0.26; 95% CI, 0.19–0.37; P < 0.0001; Fig. 1a) as
well as high cytogenetic risk (12.6months vs 6.2months;
HR, 0.41; 95% CI, 0.21–0.83; P = 0.0106; Fig. 1b) in the ITT
population. Among a subset of patients who had received 1
prior line of therapy, treatment with D-Vd prolonged me-
dian PFS versus Vd in patients with standard cytogenetic
risk (29.8months vs 7.5months; HR, 0.25; 95% CI, 0.15–
0.42; P < 0.0001; Fig. 1c) and high cytogenetic risk
(20.1months vs 8.4months; HR, 0.20; 95% CI, 0.06–0.62;
P = 0.0026; Fig. 1d).
Higher overall response rate was achieved with D-Vd
versus Vd (standard risk, 84% vs 62%; P < 0.0001; high
risk, 85% vs 56%; P = 0.0512), including deep responses
of CR or better (standard risk, 28% vs 10%; high risk,
28% vs 6%) and VGPR or better (standard risk, 62% vs
28%; P < 0.0001; high risk, 59% vs 32%; P = 0.1259;
Table 3). Median time to VGPR or better was decreased
with D-Vd compared with Vd in patients with standard
cytogenetic risk (3.5 months vs not estimable; HR, 2.16;
95% CI, 1.46–3.20; P < 0.0001) and high cytogenetic risk
(3.5 months vs 6.2 months; HR, 1.96; 95% CI, 0.86–4.45;
P = 0.1004).
Rates of MRD negativity at the 10−5 sensitivity thresh-
old were higher with D-Vd compared with Vd in
patients with standard cytogenetic risk (11% vs 3%;
Fig. 1 PFS based on cytogenetic risk status. PFS in the ITT/biomarker risk population (patients in the ITT population who met the biomarker
criteria for risk assessment): a standard cytogenetic risk patients and b high cytogenetic risk patients. PFS in patients with 1 prior line of therapy:
c standard cytogenetic risk patients and d high cytogenetic risk patients. CI, confidence interval; D-Vd, daratumumab plus bortezomib/
dexamethasone; HR, hazard ratio; ITT intent-to-treat; PFS, progression-free survival; Vd, bortezomib/dexamethasone
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P = 0.0091) and high cytogenetic risk (15% vs 0%;
P = 0.0271; Table 3). MRD negativity was sustained for
at least 6 months in a greater number of patients treated
with D-Vd versus Vd, regardless of cytogenetic risk sta-
tus. MRD negativity was sustained for at least 12 months
in 2 (1%) patients with standard cytogenetic risk and 3
(8%) patients with high cytogenetic risk in the D-Vd
group compared with none in both cytogenetic risk cat-
egories in the Vd group.
Median PFS2 was prolonged with D-Vd compared with
Vd in the standard cytogenetic risk (34.2 months vs 18.5
months; HR, 0.41; 95% CI, 0.30–0.58; P < 0.0001; Fig. 2a)
and high cytogenetic risk (28.1 months vs 19.7months;
HR, 0.58; 95% CI, 0.30–1.10; P = 0.0915; Fig. 2b) sub-
groups. Among the subset of patients with 1 prior line of
therapy, median PFS2 was prolonged with D-Vd versus
Vd in patients with standard cytogenetic risk (not estim-
able vs 23.4months; HR, 0.43; 95% CI, 0.26–0.72;
P = 0.0009; Fig. 2c). For patients with high cytogenetic
risk, median PFS2 was prolonged with D-Vd versus Vd
(34.9months vs 25.1months; HR, 0.54; 95% CI, 0.21–1.39;
P = 0.1951; Fig 2d).
At the time of the analysis, among patients with high
cytogenetic risk, 21 deaths were observed in the D-Vd
group versus 23 deaths in the Vd group. The overall sur-
vival data are immature and follow-up for overall sur-
vival is ongoing.
Updated safety results
The most frequent any grade treatment-emergent ad-
verse events observed in at least 25% of patients and the
most frequent grade 3/4 treatment-emergent adverse
events observed in at least 5% of patients are summa-
rized in Table 4. Treatment discontinuation rates due to
treatment-emergent adverse events were similar between
treatment groups for patients with standard cytogenetic
risk (11 [8%] patients in the D-Vd group and 14 [10%]
of patients in the Vd group) and among patients with
high cytogenetic risk (4 [10%] patients in the D-Vd
group and 3 [9%] patients in the Vd group).
Discussion
After a median follow-up of more than 3 years, D-Vd
continued to demonstrate substantially improved effi-
cacy in terms of PFS compared with Vd alone in pa-
tients with RRMM, regardless of cytogenetic risk
status. D-Vd reduced the risk of disease progression
or death by 74% versus Vd alone in patients with
standard cytogenetic risk and by 59% in patients with
high cytogenetic risk. Among patients treated with
D-Vd, median PFS was 16.6 months in patients with
standard cytogenetic risk (vs 6.6 months with Vd;
P < 0.0001) and 12.6 months in patients with high
cytogenetic risk (vs 6.2 months with Vd; P = 0.0106).
The PFS benefit of D-Vd over Vd was especially pro-
nounced in the subset of patients who received 1
prior line of therapy, reducing the risk of disease pro-
gression or death by 75% and 80% in patients with
standard and high cytogenetic risk, respectively. D-Vd
achieved deep responses compared with Vd, with
higher rates of VGPR or better and CR or better, re-
gardless of cytogenetic risk status. Rates of MRD
Table 3 Response and MRD-negativity rates in patients with standard and high cytogenetic risk
Standard risk High riska
Response, n (%)b D-Vd (n = 135) Vd (n = 134) P value D-Vd (n = 39) Vd (n = 34) P value
ORR 113 (84) 83 (62) < 0.0001 33 (85) 19 (56) 0.0512
≥ CRc 38 (28) 13 (10) 11 (28) 2 (6)
sCR 12 (9) 3 (2) 4 (10) 0
CR 26 (19) 10 (8) 7 (18) 2 (6)
≥ VGPRd 83 (62) 38 (28) < 0.0001 23 (59) 11 (32) 0.1259
VGPR 45 (33) 25 (19) 12 (31) 9 (27)
PR 30 (22) 45 (34) 10 (26) 8 (24)
MRD negative (10−5)e
n (%) 16 (11) 4 (3) 0.0091 6 (15) 0 0.0271
Sustained MRD negativity (≥ 6 months), n (%) 9 (6) 3 (2) 0.1374 5 (13) 0 0.0569
Sustained MRD negativity (≥ 12 months), n (%) 2 (1) 0 0.4982 3 (8) 0 0.2432
CR complete response, D-Vd daratumumab plus bortezomib/dexamethasone, ITT intent-to-treat, MRD minimal residual disease, ORR overall response rate,
PR partial response, sCR stringent complete response, Vd bortezomib/dexamethasone, VGPR very good partial response
aPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
bResponse-evaluable population
c≥ CR = sCR + CR
d≥ VGPR = sCR + CR + VGPR
eITT population (standard risk: D-Vd, n = 141; Vd, n = 140; high risk: D-Vd, n = 40; Vd, n = 35)
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negativity (10−5 sensitivity threshold) were higher with
D-Vd versus Vd in patients with standard cytogenetic
risk (11% vs 3%; P = 0.0091) and high cytogenetic
risk (15% vs 0%; P = 0.0271). Moreover, sustained
MRD-negative responses were observed in more pa-
tients treated with D-Vd compared with Vd regardless
of cytogenetic risk status. D-Vd prolonged median
PFS2 versus Vd alone in both cytogenetic risk sub-
groups. Overall, improved outcomes were achieved by
D-Vd versus Vd in patients with high cytogenetic
risk, but clinical benefits were of lesser magnitude
than D-Vd in patients with standard cytogenetic risk.
The safety profile of D-Vd in standard and high cyto-
genetic risk subgroups was consistent with the overall
population of CASTOR. No new safety signals were
identified.
The results reported here after extended follow-up fur-
ther strengthen results reported after a median follow-
up of 13.0 months [18]. In this earlier analysis in patients
with high cytogenetic risk, PFS was prolonged with
D-Vd versus Vd (median 11.2 months vs 7.2 months;
HR, 0.49; 95% CI, 0.27–0.89; P = 0.0167). With a median
follow-up of 40.0 months, the efficacy of D-Vd versus
Vd in these high-risk patients was maintained, with pro-
longed median PFS (HR, 0.41) and higher MRD-negativ-
ity rates (15% vs 0%; P = 0.0271) in this difficult-to-treat
patient population.
While cross-trial comparisons should be approached
with caution, especially due to lack of consensus on
thresholds for risk groups, the efficacy of D-Vd in pa-
tients with high cytogenetic risk appears favorable to
that reported in other studies of proteasome inhibitor–
Fig. 2 PFS2 based on cytogenetic risk status. PFS2 in the ITT/biomarker risk population (patients in the ITT population who met the biomarker
criteria for risk assessment): a standard cytogenetic risk patients and b high cytogenetic risk patients. PFS2 in patients with 1 prior line of therapy:
c standard cytogenetic risk patients and d high cytogenetic risk patients. CI, confidence interval; D-Vd, daratumumab plus bortezomib/
dexamethasone; HR, hazard ratio; ITT intent-to-treat; PFS2, progression-free survival on the subsequent line of therapy;
Vd, bortezomib/dexamethasone
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containing regimens in RRMM (Table 5). In a pre-
planned subgroup analysis of the ENDEAVOR study
based on baseline cytogenetic risk, carfilzomib in com-
bination with dexamethasone reduced the risk of disease
progression or death by 35% versus Vd in patients with
high-risk RRMM (defined as t[4;14] or t[14;16] in ≥ 10%
of screened plasma cells or del17p in ≥ 20% of screened
plasma cells assessed by FISH) [19]. Median PFS was 8.8
months with carfilzomib in combination with dexa-
methasone versus 6.0 months with Vd in patients with
high cytogenetic risk (HR, 0.65; 95% CI, 0.45–0.92;
P = 0.0075) and CR or better rates were 16% versus 4%,
respectively. In a pre-planned subgroup analysis of the
phase 3 ASPIRE study, among patients with high
Table 4 Most common any-grade (≥ 25% of patients) and grade 3/4 (≥ 5% of patients) TEAEs
Any grade Grade 3/4
Standard risk High riska Standard risk High riska
TEAE, n (%)
D-Vd
(n = 137)
Vd
(n = 136)
D-Vd
(n = 40)
Vd
(n = 34)
D-Vd
(n = 137)
Vd
(n = 136)
D-Vd
(n = 40)
Vd
(n = 34)
Hematologic
Thrombocytopenia 85 (62) 58 (43) 24 (60) 16 (47) 65 (47) 45 (33) 19 (48) 12 (35)
Anemia 45 (33) 41 (30) 7 (18) 14 (41) 25 (18) 23 (17) 4 (10) 6 (18)
Neutropenia 29 (21) 16 (12) 9 (23) 3 (9) 21 (15) 6 (4) 6 (15) 2 (6)
Lymphopenia 18 (13) 5 (4) 4 (10) 4 (12) 14 (10) 3 (2) 3 (8) 3 (9)
Leukopenia 15 (11) 5 (4) 3 (8) 3 (9) 5 (4) 1 (1) 1 (3) 2 (6)
Nonhematologic
Peripheral sensory neuropathy 67 (49) 50 (37) 22 (55) 13 (38) 4 (3) 8 (6) 2 (5) 4 (12)
Upper respiratory tract infection 43 (31) 20 (15) 15 (38) 8 (24) 1 (1) 0 3 (8) 1 (3)
Diarrhea 42 (31) 35 (26) 11 (28) 6 (18) 6 (4) 2 (2) 1 (3) 0
Cough 40 (29) 19 (14) 9 (23) 4 (12) 0 0 0 0
Fatigue 25 (18) 40 (29) 17 (43) 8 (24) 6 (4) 5 (4) 2 (5) 1 (3)
Back pain 24 (18) 15 (11) 13 (33) 1 (3) 3 (2) 0 1 (3) 0
Insomnia 22 (16) 20 (15) 11 (28) 5 (15) 2 (2) 0 0 1 (3)
Pneumonia 22 (16) 20 (15) 5 (13) 4 (12) 15 (11) 14 (10) 2 (5) 3 (9)
Asthenia 15 (11) 19 (14) 4 (10) 9 (27) 1 (1) 3 (2) 0 1 (3)
Hypertension 15 (11) 5 (4) 4 (10) 1 (3) 9 (7) 1 (1) 2 (5) 0
Decreased appetite 14 (10) 8 (6) 10 (25) 1 (3) 0 1 (1) 1 (3) 0
Spinal pain 4 (3) 3 (2) 2 (5) 0 1 (1) 0 2 (5) 0
Gastroenteritis 2 (2) 3 (2) 2 (5) 1 (3) 0 2 (2) 2 (5) 1 (3)
Squamous cell carcinoma of
the skin
0 0 2 (5) 0 0 0 2 (5) 0
TEAE treatment-emergent adverse event, D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone
aPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality
Table 5 Summary of median PFS of high cytogenetic risk patients with RRMM in randomized, phase 3 trials
Trial name High cytogenetic risk definition Arm 1 (n) Arm
2 (n)
Arm 1 median
PFS, months
Arm 2 median
PFS, months
Hazard ratio
(95% CI);
P value
CASTOR t(4;14), t(14;16), or del17p assessed by FISH or karyotyping D-Vd (40) Vd
(35)
12.6 6.2 0.41 (0.21–0.83);
0.0106
ENDEAVOR
[19]
t(4;14) or t(14;16) in ≥ 10% of screened plasma cells or del17p
in ≥ 20% of screened plasma cells assessed by FISH
Kd (97) Vd
(113)
8.8 6.0 0.65 (0.45–0.92);
0.0075
ASPIRE [20] t(4;14), t(14;16), or del17p (in ≥ 60% of screened plasma cells)
assessed by FISH
KRd (48) Rd
(52)
23.1 13.9 0.70 (0.43–1.16);
0.0829
PANORAMA-1
[21]
t(4;14), t(14;16), or del17p assessed by FISH Panobinostat
plus Vd
Vd – – 0.47 (0.18–1.25)
CI confidence interval, D-Vd daratumumab plus bortezomib/dexamethasone, FISH fluorescence in situ hybridization, Kd carfilzomib/dexamethasone,
KRd carfilzomib/lenalidomide/dexamethasone, PFS progression-free survival, Rd lenalidomide/dexamethasone, Vd bortezomib/dexamethasone
Weisel et al. Journal of Hematology & Oncology          (2020) 13:115 Page 8 of 11
cytogenetic risk (t[4;14], t[14;16], or del17p in ≥ 60% of
screened plasma cells assessed by FISH), median PFS
was 23.1 months with carfilzomib plus Rd versus 13.9
months with Rd alone (HR, 0.70; 95% CI, 0.43–1.16;
P = 0.0829) [20]. In the phase 3 PANORAMA-1 trial of
panobinostat plus Vd versus Vd alone in RRMM, the
HR for median PFS in high-risk patients (t[4;14],
t[14;16], or del17p assessed by FISH) was 0.47 (95% CI,
0.18–1.25) in favor of panobinostat-Vd [21].
The efficacy of daratumumab plus standard of care, regard-
less of cytogenetic risk status, was also demonstrated in the
phase 3 POLLUX study of daratumumab plus Rd versus Rd
alone in RRMM [22]. At a median follow-up of more than 3
years, median PFS was prolonged with daratumumab plus Rd
(D-Rd) versus Rd in patients with standard (not reached vs
19.9months; HR, 0.41; 95% CI, 0.31–0.55; P < 0.0001) and
high (26.8 vs 8.8months; HR, 0.54; 95% CI, 0.32–0.91;
P = 0.0175) cytogenetic risk, and deep responses were
achieved with D-Rd in both cytogenetic risk subgroups. It is
noteworthy that D-Vd and D-Rd, but not Vd nor Rd, achieved
MRD negativity in patients with high cytogenetic risk, which
suggests that targeting CD38 in combination with other stand-
ard of care regimens helps improve the historically poor out-
comes observed in this patient population [23–27]. Looking
ahead, there continues to be a gap in treatment options for
high-risk patients with RRMM; potential treatment regimens
that can be studied include daratumumab in combination
with pomalidomide, carfilzomib, or bortezomib, lenalidomide,
and dexamethasone.
This report is limited by incomplete cytogenetic ab-
normality data collected for patients enrolled in the
CASTOR study; cytogenetic testing was not performed
in 29% of patients in the study. Cytogenetic testing was
performed locally and no per-protocol specific cut-off
values were used for defining the presence of genetic ab-
normalities; cut-off values used at each site were not col-
lected. Additionally, MRD was not assessed in patients
with VGPR and in 16% of patients with CR or better. Of
patients with available cytogenetic abnormality data, pa-
tients without MRD assessment were considered MRD
positive, potentially underestimating the rate of MRD
negativity. Lastly, small sample sizes in the cytogenetic
risk subgroups precluded us from conducting a multi-
variate analysis to account for baseline differences.
Conclusions
In this subgroup analysis, D-Vd demonstrated a clear ef-
ficacy benefit compared with Vd in patients with RRMM
and high cytogenetic risk in CASTOR. When combined
with the recently updated POLLUX results, these find-
ings reinforce the effectiveness and tolerability of daratu-
mumab plus standard of care as a treatment for MM,
regardless of cytogenetic risk status.
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